Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
EA-230 is a newly developed synthetic compound with anti-inflammatory properties, it is a
linear tetrapeptide derived from the human chorionic gonadotropin hormone (hCG). Recently,
its immunomodulatory effects in humans were confirmed in a phase I trial and an optimal dose
was established. To establish this anti-inflammatory effect in a selected patient population
and assess clinical outcome, a combined phase IIa/IIb trial will be conducted with patients
undergoing cardiac surgery.